Hims Weight Loss Review – Big, Credentialed, and Out of the Compounding Business

Hims is one of the largest direct-to-consumer telehealth companies in the US, publicly listed and operating across sexual health, hair loss, mental health and weight management. Its GLP-1 programme charges $39 for a first month and $149 a month thereafter, with medication billed on top — and, following a legal dispute with Novo Nordisk that settled in March 2026, that medication is now FDA-approved brand-name product rather than the compounded semaglutide it briefly sold at $49. That episode is the most useful thing to understand about Hims, and it is where this review starts.

Overview

Hims operates at a scale almost nothing else on this site matches: a publicly traded company filing audited accounts, with tens of thousands of independent reviews and an established prescribing infrastructure. That alone puts it in a different accountability bracket from the month-old LLCs that dominate the compounded GLP-1 market.

The $49 Pill and the Novo Nordisk Settlement

How you read that depends on what you were hoping to buy. If you wanted a $49 GLP-1, the answer is that it no longer exists here. But for anyone weighing compounded against approved medication, the episode is genuinely informative: a very large, well-resourced company launched a compounded semaglutide product and exited it within five weeks under manufacturer pressure. That is the clearest signal yet of how exposed the compounded GLP-1 market is — and it happened alongside the FDA writing to around 30 telehealth companies over compounded GLP-1 marketing, and proposing on 30 April 2026 to exclude semaglutide and tirzepatide from the 503B bulks list.

The practical consequence is that Hims now sells FDA-approved medication. That is more expensive than compounded alternatives and considerably more durable. Our compounded vs brand-name guide covers the trade-off.

Hims at a Glance

Pricing: Membership Plus Medication

Hims charges in two parts, and both must be added together. Membership is $39 for the first month, then $149 a month. Medication is separate.

Reported medication figures vary between sources, which is why the table gives ranges. The structural point is stable: the $149 membership roughly doubles the cost of the cheapest medication. At $298 all-in for the Wegovy pill, Hims is twice what NovoCare Pharmacy charges for the same approved product direct from the manufacturer, and above Ro at $223 on an annual plan.

The exception is insurance. If your plan covers a GLP-1 and you use the manufacturer savings card, medication can drop to $0–$25 and the membership becomes the main cost — at which point Hims is competitive. Check coverage first: see our insurance guide.

Eligibility, Contraindications, and Side Effects

Because Hims now prescribes only approved products, eligibility follows the approved indications, assessed by a licensed provider. See our eligibility guide.

Semaglutide and tirzepatide carry a boxed warning regarding thyroid C-cell tumours, based on rodent studies. You should not take these medications if you or a family member have had medullary thyroid carcinoma, if you have Multiple Endocrine Neoplasia syndrome type 2, or if you have had a serious hypersensitivity reaction to the active ingredient. They are not for use in pregnancy. A history of pancreatitis, gallbladder disease, gastroparesis or other severe gastrointestinal disease, or diabetic retinopathy, warrants specific discussion first.

Common side effects are gastrointestinal — nausea, vomiting, diarrhoea, constipation and abdominal pain — worst after a dose increase. Serious but less common risks include pancreatitis, gallbladder disease and acute kidney injury from dehydration. Our side effects guide covers management.

One advantage of Hims's current position: because it dispenses approved products, the published trial evidence for those products genuinely applies — unlike the compounded market, where transposing trial results is the practice the FDA has been writing letters about.

Legitimacy and Complaint Record

Hims holds an A+ BBB accreditation with an average around 3.8 stars across roughly 7,277 reviews, and about 3.4 out of 5 on Trustpilot. For a company of this size those are respectable rather than outstanding numbers, and the sample is large enough to be meaningful.

The recurring criticisms concern cost, customer service and medication access rather than clinical safety. One specific and fair criticism: public complaint responses on both Trustpilot and the BBB are generic and templated, acknowledging concerns and directing people to support without engaging with the specifics. That is a scale problem, and it contrasts with smaller operators like MEDVi that write individual replies.

How Hims Compares

Ro offers the same category of approved medication with a cheaper membership tier. NovoCare sells the drug direct with no membership at all if you have a prescriber. Hims's advantage is breadth — one account covering weight loss, hair, sexual and mental health — rather than price.

Pros and Cons

Who Should Pick It, and Who Should Look Elsewhere

Hims suits you if your insurance covers a GLP-1 — at $0–$25 medication plus the membership it is a solid, well-credentialed option — or if you already use Hims for something else and value one account and one clinical record across several conditions. The scale, the A+ accreditation and the approved-medication-only policy are all genuine strengths.

Look elsewhere if you are paying cash. NovoCare Pharmacy sells the same approved semaglutide at $149 with no membership, and Ro reaches $223 all-in on an annual plan. And if you came for the $49 compounded pill, it is no longer available to new patients.

Limitations of This Review

This review is based on independent coverage, BBB records and review platforms, checked on 7 August 2026. Reported medication prices differ between sources, so we have given ranges rather than single figures; confirm your own quote. Insurance outcomes vary by plan and we have not tested Hims's insurance handling. We could not obtain the settlement terms with Novo Nordisk, only that a settlement occurred on 9 March 2026 and that compounded semaglutide was subsequently withdrawn for new patients. We have not signed up or been prescribed.

Frequently Asked Questions

Verdict

Hims is a serious company and the approved-medication-only position is the right one to be in as the FDA tightens compounded GLP-1 supply. The A+ accreditation and the scale of its review base mean you are not gambling on whether the medicine arrives. But the $149 membership on top of medication makes cash pricing uncompetitive against buying the identical approved drug direct, and the templated complaint handling is a poor look for a company this well resourced. Check your insurance; that answer decides whether this is a good deal.